Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting | ||
By: PR Newswire Association LLC. - 16 Apr 2024 | Back to overview list |
|
Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel, April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that it will present preliminary data from its Phase 1 study of BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in refractory patients with either non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma (RCC), who previously progressed on immunotherapy, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The conference will take place at McCormick Place in Chicago, Illinois, and will also be available virtually from May 31 to June 4, 2024.
Presentation Details: Title: Preliminary results from a First-in-Human (FIH), open-label Phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab. Dr. Elran Haber, CEO of Biomica, stated: "We look forward to presenting our preliminary data at ASCO, and to provide initial safety and efficacy results from our ongoing Phase 1 POC trial evaluating BMC-128 in combination with nivolumab in refractory patients. These results mark significant progress, laying the groundwork for the next phase in our clinical development process". Additional information about the trial, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT05354102). About BMC128: About Biomica Ltd.: About Evogene Ltd.: Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus and castor varieties for the biofuel and other industries, by Casterra. For more information, please visit www.evogene.com. Forward-Looking Statements: This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statement in this press release when they discusses safety and efficacy results from Biomica's Phase 1 POC trial evaluating BMC-128 in combination with nivolumab in refractory patients, and the progress to the next phase in its clinical development process. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel and Hamas and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact Logo - https://mma.prnewswire.com/media/1974949/Biomica_Logo.jpg View original content:https://www.prnewswire.com/news-releases/biomica-to-present-at-the-american-society-of-clinical-oncology-asco-2024-annual-meeting-302117932.html SOURCE Biomica Ltd. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |